2017

There’s a lot of ways to leave a good impression

Tuesday, October 10, 2017

The Pulse on Study Conduct by Elizabeth Weeks-Rowe

There is no better learning opportunity than to observe an experienced individual correctly complete a process that you are trying to understand/implement outside of a classroom in a real-world environment. It lends depth to the sometimes-lifeless instruction of written curriculum. The demonstration tames the daunting unknown, creating confidence in an ability where there may have been none. It shows diversity of technique and timing, and expands that which is preconceived about an untried task.

[Read More]

CTTI takes on site investigator turnover in new recommendations

Friday, October 6, 2017

The Clinical Trials Transformation Initiative (CTTI) unveiled new recommendations aimed at reducing high rates of turnover among U.S. clinical trial site investigators at the Society for Clinical Research Sites (SCRS) Global Site Solutions Summit on Oct. 7. CTTI’s practical solutions address the administrative, financial, and logistical burdens that are causing investigators to abandon clinical research.

[Read More]

Research!America announces 2018 Advocacy Awards Honorees

Friday, October 6, 2017

A former congressional leader who was instrumental in doubling the NIH budget, the head of a global research center aimed at reducing the burden of disease, two long-time mental health advocates dedicated to accelerating research, a rare disease organization committed to biotech innovation, and a world-renowned vaccine researcher are among those who will be honored at Research!America’s 22nd annual Advocacy Awards on Wednesday, March 14, 2018, in Washington, D.C. The honorees for the Isadore Rosenfeld Award for Impact on Public Opinion and the Edwin C. Whitehead Award for Medical Research Advocacy will be announced in the coming weeks.

[Read More]

Bioclinica moves to New Princeton, New Jersey Office

Friday, October 6, 2017

Bioclinica, a provider of scientific-enabled Medical Imaging and eHealth solutions in clinical trials, hosted New Jersey Lt. Governor Kim Guadagno, clients and partners in an open house to celebrate the official opening of its new and larger Princeton, New Jersey facility. Following an official ribbon-cutting, guests toured the space, getting an insider’s view into the company’s work, which has supported the global regulatory approvals of more than 150 new medical treatments in Oncology, Neurosciences, Musculoskeletal and other therapeutic areas.

[Read More]

SynteractHCR moves headquarters to Carlsbad, California

Friday, October 6, 2017

SynteractHCR, a full-service global CRO, has recently moved to its expansive new facility in Carlsbad, California. The approximately 38,000 square feet of space at 5909 Sea Otter Place has been designed with an open concept to foster collaboration and creates a dynamic team environment, right in line with the company’s innovative business philosophy. Headquartered in San Diego County, with additional offices in the Research Triangle Park (RTP) area of North Carolina as well as 10 additional offices in Western, Central, and Eastern Europe, SynteractHCR sits in six of the top 10 biotech centers in the world and supports clients in conducting clinical trials worldwide.

[Read More]

Ultragenyx to acquire Dimension Therapeutics

Wednesday, October 4, 2017

Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Dimension Therapeutics have entered into a definitive merger agreement under which Ultragenyx will acquire all of the outstanding shares of common stock of Dimension for $6.00 per share, or approximately $151 million in cash, based on currently outstanding shares. The transaction is structured as a tender offer and will be funded through Ultragenyx’s existing cash resources.

[Read More]

Mitochon Pharmaceuticals to support mitochondrial research in Parkinson’s

Wednesday, October 4, 2017

Mitochon Pharmaceuticals announced that it was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help develop its mitochondrial targeted compounds for treating Parkinson’s disease. The funding will go to pivotal animal studies to assess the benefits of Mitochon’s compounds in ameliorating the deficits associated with dopaminergic neuron loss, the hallmark of Parkinson’s disease. If successful, Mitochon’s compounds, MP101 ad MP201 could be in patients as early as 2019.

[Read More]